Back to Archived Journals » Biosimilars » Volume 3

Rituximab and biosimilars – equivalence and reciprocity

Authors Qureshi ZP, Magwood JS, Singh S, Bennett CL

Received 19 June 2012

Accepted for publication 6 January 2013

Published 14 June 2013 Volume 2013:3 Pages 19—25


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Zaina P Qureshi,1,2 Jametta S Magwood,1 Sarveshwari Singh,3 Charles L Bennett1,2,4

1South Carolina College of Pharmacy, Columbia, SC, USA; 2Arnold School of Public Health of the University of South Carolina, Columbia, SC, USA; 3Department of Biological Sciences, George Washington University, Washington, DC, USA; 4Hollings Cancer Center, Charleston, SC, USA

Abstract: Cancer is a debilitating disease affecting millions of people daily. Over the years, cancer treatment has advanced in leaps and bounds. Antibodies are important breakthrough therapeutic agents for cancer. These agents, proteins produced by B lymphocytes of the immune system in response to antigens, bind to receptors on cell surfaces so that the antigen–antibody complexes can be recognized and destroyed by phagocytes. While each B cell synthesizes only one kind of antibody, an entire population of different types of B cells and their respective antibodies are produced in response to various antigens to which the organism had been exposed. However, to be useful clinically, substantial amounts of a single antibody must be generated from a single ancestral B cell. These antibodies produced by a specific population of B cells are the monoclonal antibodies that have become the cornerstone of treatment for cancer and many immunologic illnesses. The purpose of this report is to provide an overview of the clinical development of biosimilars in clinical oncology, focusing on rituximab and like biosimilars.

Keywords: rituximab, cancer treatment, biosimilars

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]